Lurbinectedin is a drug used for the treatment of small cell lung cancer and other solid tumors. However, there is limited information on the use of lurbinectedin in infants, and the risks associated with its use in this population are not well understood.

According to the drug patent watch website [1], there are no patents related to the use of lurbinectedin in infants. However, this does not necessarily mean that lurbinectedin is safe for infants, as there may not have been enough research conducted in this area to warrant a patent.

The Mayo Clinic [2] and WebMD [3] both provide information on the potential side effects of lurbinectedin in adults, which include nausea, vomiting, fatigue, decreased appetite, and low white blood cell count. However, there is no specific information available on the risks of lurbinectedin for infants.

Given the lack of information on the use of lurbinectedin in infants, it is important for healthcare providers to carefully weigh the potential benefits and risks of this medication before prescribing it to this population. Close monitoring for any adverse effects is also recommended.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.mayoclinic.org/drugs-supplements/lurbinectedin-intravenous-route/side-effects/drg-20490804?p=1
[3] https://www.webmd.com/drugs/2/drug-179563/lurbinectedin-intravenous/details